JCS/JHRS Guideline: Rivaroxaban Not Recommended for Patients With Nonvalvular Atrial Fibrillation and High Bleeding Risk ― Reply ―
Ono K, Yu‐ki Iwasaki, Wataru Shimizu
Topics & Concepts
RivaroxabanAtrial fibrillationGuidelineMedicineMajor bleedingInternal medicineCardiologyWarfarinPathologyAtrial Fibrillation Management and OutcomesCardiac Arrhythmias and TreatmentsVenous Thromboembolism Diagnosis and Management